Small molecule · Inhibitor of DNA polymerase · developed by Ligand Pharmaceuticals
MB07133 is a prodrug of the monophosphate form of the antimetabolite cytarabine, designed to deliver cytarabine to the liver, where a liver kinase converts it to the triphosphate form. The active metabolite competes with cytidine for incorporation into DNA and inhibits DNA polymerase, slowing DNA synthesis. It is studied in hepatocellular carcinoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT00073736 | Phase 1/2 | Hepatocellular Carcinoma | Completed | LGND |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Hepatocellular Carcinoma
Updated Oct 18, 2026. Something wrong or missing? Report it on the LGND page.
See LGND's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LGND catalysts and pipeline →